188 related articles for article (PubMed ID: 37219526)
1. Simultaneous evaluation of treatment efficacy and toxicity for bispecific T-cell engager therapeutics in a humanized mouse model.
Yang J; Jiao J; Draheim KM; Yang G; Yang H; Yao LC; Shultz LD; Greiner DL; Rajagopal D; Vessillier S; Maier CC; Mohanan S; Cai D; Cheng M; Brehm MA; Keck JG
FASEB J; 2023 Jun; 37(6):e22995. PubMed ID: 37219526
[TBL] [Abstract][Full Text] [Related]
2. A rapid, sensitive, and reproducible in vivo PBMC humanized murine model for determining therapeutic-related cytokine release syndrome.
Ye C; Yang H; Cheng M; Shultz LD; Greiner DL; Brehm MA; Keck JG
FASEB J; 2020 Sep; 34(9):12963-12975. PubMed ID: 32772418
[TBL] [Abstract][Full Text] [Related]
3. Establishment of Humanized Mice from Peripheral Blood Mononuclear Cells or Cord Blood CD34+ Hematopoietic Stem Cells for Immune-Oncology Studies Evaluating New Therapeutic Agents.
Verma B; Wesa A
Curr Protoc Pharmacol; 2020 Jun; 89(1):e77. PubMed ID: 32453514
[TBL] [Abstract][Full Text] [Related]
4. TNB-486 induces potent tumor cell cytotoxicity coupled with low cytokine release in preclinical models of B-NHL.
Malik-Chaudhry HK; Prabhakar K; Ugamraj HS; Boudreau AA; Buelow B; Dang K; Davison LM; Harris KE; Jorgensen B; Ogana H; Pham D; Schellenberger U; Van Schooten W; Buelow R; Iyer S; Trinklein ND; Rangaswamy US
MAbs; 2021; 13(1):1890411. PubMed ID: 33818299
[TBL] [Abstract][Full Text] [Related]
5. Myeloid and dendritic cells enhance therapeutics-induced cytokine release syndrome features in humanized BRGSF-HIS preclinical model.
Martin GH; Gonon A; Martin-Jeantet P; Renart-Depontieu F; Biesova Z; Cifuentes A; Mukherjee A; Thisted T; Doerner A; Campbell DO; Bourré L; van der Horst EH; Rezza A; Thiam K
Front Immunol; 2024; 15():1357716. PubMed ID: 38384461
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of a TGN1412 analogue using in vitro assays and two immune humanized mouse models.
Yan H; Bhagwat B; Sanden D; Willingham A; Tan A; Knapton AD; Weaver JL; Howard KE
Toxicol Appl Pharmacol; 2019 Jun; 372():57-69. PubMed ID: 30914376
[TBL] [Abstract][Full Text] [Related]
7. Lack of acute xenogeneic graft- versus-host disease, but retention of T-cell function following engraftment of human peripheral blood mononuclear cells in NSG mice deficient in MHC class I and II expression.
Brehm MA; Kenney LL; Wiles MV; Low BE; Tisch RM; Burzenski L; Mueller C; Greiner DL; Shultz LD
FASEB J; 2019 Mar; 33(3):3137-3151. PubMed ID: 30383447
[TBL] [Abstract][Full Text] [Related]
8. Promising preclinical platform for evaluation of immuno-oncology drugs using Hu-PBL-NSG lung cancer models.
Pyo KH; Kim JH; Lee JM; Kim SE; Cho JS; Lim SM; Cho BC
Lung Cancer; 2019 Jan; 127():112-121. PubMed ID: 30642538
[TBL] [Abstract][Full Text] [Related]
9. NOD/scid IL-2Rg(null) mice: a preclinical model system to evaluate human dendritic cell-based vaccine strategies in vivo.
Spranger S; Frankenberger B; Schendel DJ
J Transl Med; 2012 Feb; 10():30. PubMed ID: 22364226
[TBL] [Abstract][Full Text] [Related]
10. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
11. JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy.
Leclercq G; Haegel H; Toso A; Zimmermann T; Green L; Steinhoff N; Sam J; Pulko V; Schneider A; Giusti AM; Challier J; Freimoser-Grundschober A; Larivière L; Odermatt A; Stern M; Umana P; Bacac M; Klein C
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35064010
[TBL] [Abstract][Full Text] [Related]
12. Antitumor Effect of Programmed Death-1 (PD-1) Blockade in Humanized the NOG-MHC Double Knockout Mouse.
Ashizawa T; Iizuka A; Nonomura C; Kondou R; Maeda C; Miyata H; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Katano I; Ito M; Akiyama Y
Clin Cancer Res; 2017 Jan; 23(1):149-158. PubMed ID: 27458246
[TBL] [Abstract][Full Text] [Related]
13. Development of novel major histocompatibility complex class I and class II-deficient NOD-SCID IL2R gamma chain knockout mice for modeling human xenogeneic graft-versus-host disease.
Pino S; Brehm MA; Covassin-Barberis L; King M; Gott B; Chase TH; Wagner J; Burzenski L; Foreman O; Greiner DL; Shultz LD
Methods Mol Biol; 2010; 602():105-17. PubMed ID: 20012395
[TBL] [Abstract][Full Text] [Related]
14. Human endoglin-CD3 bispecific T cell engager antibody induces anti-tumor effect
Zhong L; Shi W; Gan L; Liu X; Huo Y; Wu P; Zhang Z; Wu T; Peng H; Huang Y; Zhao Y; Yuan Y; Deng Z; Tang H
Theranostics; 2021; 11(13):6393-6406. PubMed ID: 33995664
[No Abstract] [Full Text] [Related]
15. Improved engraftment of human peripheral blood mononuclear cells in NOG MHC double knockout mice generated using CRISPR/Cas9.
Ka Y; Katano I; Nishinaka E; Welcker J; Mochizuki M; Kawai K; Goto M; Tomiyama K; Ogura T; Yamamoto T; Ito M; Ito R; Takahashi R
Immunol Lett; 2021 Jan; 229():55-61. PubMed ID: 33253759
[TBL] [Abstract][Full Text] [Related]
16. [Establishment of a cytokine release syndrome associated with chimeric antigen receptor T cell treatment in SCID/Beige mice model].
Shan JQ; Nan SF; Li F; Shen CY; Zhang Y
Zhonghua Zhong Liu Za Zhi; 2021 Dec; 43(12):1248-1254. PubMed ID: 34915632
[No Abstract] [Full Text] [Related]
17. A Simple Mouse Model for the Study of Human Immunodeficiency Virus.
Kim KC; Choi BS; Kim KC; Park KH; Lee HJ; Cho YK; Kim SI; Kim SS; Oh YK; Kim YB
AIDS Res Hum Retroviruses; 2016 Feb; 32(2):194-202. PubMed ID: 26564392
[TBL] [Abstract][Full Text] [Related]
18. Evaluating Human Immune Responses for Vaccine Development in a Novel Human Spleen Cell-Engrafted NOD-SCID-IL2rγNull Mouse Model.
Ghosn S; Chamat S; Prieur E; Stephan A; Druilhe P; Bouharoun-Tayoun H
Front Immunol; 2018; 9():601. PubMed ID: 29628927
[TBL] [Abstract][Full Text] [Related]
19. Use of human splenocytes in an innovative humanised mouse model for prediction of immunotherapy-induced cytokine release syndrome.
Matas-Céspedes A; Brown L; Mahbubani KT; Bareham B; Higgins J; Curran M; de Haan L; Lapointe JM; Stebbings R; Saeb-Parsy K
Clin Transl Immunology; 2020; 9(11):e1202. PubMed ID: 33173582
[TBL] [Abstract][Full Text] [Related]
20. Xenogeneic graft-versus-host-disease in NOD-scid IL-2Rγnull mice display a T-effector memory phenotype.
Ali N; Flutter B; Sanchez Rodriguez R; Sharif-Paghaleh E; Barber LD; Lombardi G; Nestle FO
PLoS One; 2012; 7(8):e44219. PubMed ID: 22937164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
